Advertisement
Organisation › Details
Novo Nordisk A/S
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. *
Group | Novo Group (Group) | |
Industry | pharmaceutical | |
Industry 2 | antidiabetic | |
Region | Bagsværd | |
Country | Denmark | |
Street | Novo Allé | |
City | 2880 Bagsværd | |
Tel | 45-4444-8888 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | H: 10,001 to 50,00 (2021-12-13) |
Currency | DKK | |
Annual sales | 111,696,000,000 (sales, net, consolidated (2017) 2017-12-31) | |
Profit | 38,130,000 (2017-12-31) | |
Cash | 18,852,000,000 (2017-12-31) | |
* Document for »About Section«: Novo Nordisk A/S. (12/13/21). "Press Release: Novo Nordisk Invests more than DKK 17 bn in Expansion of the Manufacturing Facilities in Kalundborg, Denmark". | ||
Record changed: 2024-03-26 |
Advertisement
More documents for Novo Group (Group)
- [1] Cardior Pharmaceuticals GmbH. (3/25/24). "Press Release: Novo Nordisk to Acquire Cardior Pharmaceuticals and Strengthen Pipeline in Cardiovascular Disease". Bagsværd & Hannover....
- [2] Novo Nordisk A/S. (1/4/24). "Press Release: Novo Nordisk Enters into Research Collaborations with Omega Therapeutics and Cellarity on Novel Treatment Approaches for Cardiometabolic Diseases". Bagsværd, Cambridge, MA & Somerville, MA....
- [3] LimmaTech Biologics AG. (10/9/23). "Press Release: LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections". Schlieren....
- [4] Novo Nordisk A/S. (9/25/23). "Press Release: Valo Health and Novo Nordisk to Collaborate to Discover and Develop Novel Treatments for Cardiometabolic Diseases Using Human Data and Artificial Intelligence". Bagsværd & Boston, MA....
- [5] Embark Laboratories ApS. (8/30/23). "Press Release: Novo Nordisk Acquires Embark Biotech, including Its Lead Asset Targeting Obesity and other Cardiometabolic Diseases". Copenhagen....
- [6] Novo Nordisk A/S. (8/10/23). "Press Release: Novo Nordisk to Acquire Inversago Pharma to Develop New Therapies for People Living with Obesity, Diabetes and other Serious Metabolic Diseases". Bagsværd & Montreal....
- [7] Bactolife A/S. (8/8/23). "Press Release: Bactolife Raises EUR 30 Million in Series A Financing". Copenhagen....
- [8] BioGeneration Ventures B.V.. (7/13/23). "Press Release: BioGeneration Ventures Closes BGV Fund V at €150 Million". Naarden....
- [9] EQT AB. (6/21/23). "Press Release: EQT Private Equity to Sell Ellab, Following Transformation into a Leading Validation & Monitoring Provider for the Biotech and Pharmaceutical Industries"....
- [10] AH Diagnostics A/S. (4/3/23). "Press Release: Helle Zacho Becomes the New CEO of the AH Diagnostics Group"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top